Eli Lilly is moving to deepen its bet on inflammatory disease, striking a deal to acquire biotech player Ventyx Biosciences ...

The sales agreement contains both financial and data-sharing provisions. PharmAla will seek to ship its LaNeo MDMA Clinical Research Materials to Østfold Hospital Trust at the earliest opportunity, ...

Biotech companies that will lead the next decade wont just have better science, theyll have superior operating models, writes ...

The experiments conducted on the International Space Station by Shubhanshu Shukla will benefit all humans on the planet.

DUBLIN, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The Trump administration’s ambition to unleash biomedical innovation and sharpen America’s edge against China is colliding with a far messier reality inside the Food and Drug Administration. Investors ...

Biopharma is back, and it’s smarter, slimmer and more strategic than before. The industry is outperforming the broader market, with the long-suffering State Street SPDR S&P Biotech exchange-traded ...

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...

The "Aseptic Processing of Pharmaceutical and Biotech Products Course (Dec 11th - Dec 12th, 2025)" training has been added to ResearchAndMarkets.com's offering. This comprehensive course covers ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company's technology has ...

The data and insights highlighted in the article are drawn from the Biotech Playbook for Progress, a comprehensive resource built from a 2025 TriNetX survey of 150 biotech and pharma executives.